Real World Study to Describe the Effectiveness and Safety of Teprotumumab Among Thyroid Eye Disease Patients
NCT07085117
·
clinicaltrials.gov ↗
COMPLETED
Status
5
Enrollment
INDUSTRY
Sponsor class
Conditions
Thyroid Eye Disease
Interventions
DRUG:
Teprotumumab
Sponsor
Amgen